Biomaterials for Cancer Therapeutics

<p>Contributor contact details</p> <p>Woodhead Publishing Series in Biomaterials</p> <p>Preface</p> <p>Chapter 1: Introduction to biomaterials for cancer therapeutics</p> <p>Abstract:</p> <p>1.1 Introduction</p> <p>1.2 Biomaterials used in cancer therapeutics</p> <p>1.3 Materials used in anticancer formulations</p> <p>1.4 Conclusion and future trends</p> <p>Chapter 2: Cancer cell biology</p> <p>Abstract:</p> <p>2.1 Introduction</p> <p>2.2 Public perception and misunderstanding of cancer cell activity</p> <p>2.3 The ‘War on Cancer’</p> <p>2.4 The genetic basis of cancer</p> <p>2.5 Cancer interface with the environment</p> <p>2.6 Cancer cells as moving targets</p> <p>2.7 Conclusion and future trends</p> <p>Chapter 3: Targeted drug delivery for cancer therapy</p> <p>Abstract:</p> <p>3.1 Introduction</p> <p>3.2 Current paradigm</p> <p>3.3 Challenges to current paradigm</p> <p>3.4 Conclusion and future trends</p> <p>Chapter 4: Chemical synthesis of carbohydrate-based vaccines against cancers</p> <p>Abstract:</p> <p>4.1 Introduction</p> <p>4.2 Semi-synthetic vaccines</p> <p>4.3 Fully synthetic vaccines</p> <p>4.4 Conclusion and future trends</p> <p>Chapter 5: Generating functional mutant proteins to create highly bioactive anticancer biopharmaceuticals</p> <p>Abstract:</p> <p>5.1 Introduction</p> <p>5.2 Artificial proteins for cancer therapy</p> <p>5.3 How to create functional mutant proteins as beneficial therapeutics</p> <p>5.4 Mutant TNFα for cancer therapy</p> <p>5.5 Conclusion and future trends</p> <p>5.6 Sources of further information and advice</p> <p>Chapter 6: Polymer therapeutics for treating cancer</p> <p>Abstract:</p> <p>6.1 Introduction</p> <p>6.2 Polyamines and polyamine analogs</p> <p>6.3 Polymeric P-glycoprotein (Pgp) inhibitors</p> <p>6.4 Conclusion and future trends</p> <p>6.5 Acknowledgment</p> <p>Chapter 7: Nanotechnology for cancer screening and diagnosis</p> <p>Abstract:</p> <p>7.1 Introduction</p> <p>7.2 Nanotechnology for cancer diagnosis</p> <p>7.3 Nanotechnology-based biosensing platforms</p> <p>7.4 Nanotechnology for biosensing – early detection of cancer</p> <p>7.5 Nanotechnology for cancer imaging</p> <p>7.6 Concerns with using nanomaterials</p> <p>7.7 Conclusion and future trends</p> <p>Chapter 8: Synergistically integrated nanomaterials for multimodal cancer cell imaging</p> <p>Abstract:</p> <p>8.1 Introduction</p> <p>8.2 Nanomaterial-based multifunctional imaging probes</p> <p>8.3 Nanoparticles with exogenous imaging ligands</p> <p>8.4 Nanoparticles with endogenous contrast</p> <p>8.5 Cocktail injection</p> <p>8.6 Conclusion</p> <p>Chapter 9: Hybrid nanocrystal as a versatile platform for cancer theranostics</p> <p>Abstract:</p> <p>9.1 Introduction</p> <p>9.2 Imaging modality</p> <p>9.3 Developing theranostic systems</p> <p>9.4 Hybrid nanocrystal as theranostic platform</p> <p>9.5 Conclusion</p> <p>9.6 Acknowledgment</p> <p>Chapter 10: Embolisation devices from biomedical polymers for intra-arterial occlusion drug delivery in the treatment of cancer</p> <p>Abstract:</p> <p>10.1 Introduction</p> <p>10.2 Biomedical polymers and embolisation agents</p> <p>10.3 Particulate embolisation agents</p> <p>10.4 Drug-eluting embolisation beads</p> <p>10.5 Polymer structure, form and property relationships</p> <p>10.6 Experience with drug-eluting embolisation beads</p> <p>10.7 Conclusions and future trends</p> <p>10.8 Acknowledgement</p> <p>Chapter 11: Small interfering RNAs (siRNAs) as cancer therapeutics</p> <p>Abstract:</p> <p>11.1 Introduction</p> <p>11.2 Prerequisites for siRNAs cancer therapeutics</p> <p>11.3 Delivery systems for anticancer siRNAs</p> <p>11.4 Current challenges for clinical trials</p> <p>11.5 Conclusion</p> <p>11.6 Acknowledgement</p> <p>Chapter 12: Reverse engineering of the low temperature-sensitive liposome (LTSL) for treating cancer</p> <p>Abstract:</p> <p>12.1 Introduction</p> <p>12.2 What is reverse engineering?</p> <p>12.3 Investigating the thermal-sensitive liposome’s performance-in-service</p> <p>12.4 Defining the function of the liposome</p> <p>12.5 Component design: mechanism of action</p> <p>12.6 Selecting the most appropriate material when designing the Dox-LTSL</p> <p>12.7 Analysis of materials performance in the design</p> <p>12.8 Specification sheet</p> <p>12.9 Production</p> <p>12.10 Prototypes</p> <p>12.11 Further development</p> <p>12.12 Conclusion and future trends</p> <p>12.13 Acknowledgements</p> <p>Chapter 13: Gold nanoparticles (GNPs) as multifunctional materials for cancer treatment</p> <p>Abstract:</p> <p>13.1 Introduction</p> <p>13.2 Physical properties of gold nanoparticles</p> <p>13.3 Surface chemistry of GNPs</p> <p>13.4 GNPs as vehicles for drug delivery</p> <p>13.5 GNPs in biomedical imaging and theranostics</p> <p>13.6 GNPs as radiosensitizing agents</p> <p>13.7 Challenges in the development of GNPs as therapeutic agents</p> <p>13.8 Conclusion and future trends</p> <p>13.9 Acknowledgments</p> <p>Chapter 14: Multifunctional nanosystems for cancer therapy</p> <p>Abstract</p> <p>14.1 Introduction</p> <p>14.2 Design of multifunctional nanosystems</p> <p>14.3 Illustrative examples of multifunctional nanosystems for tumor-targeted therapies</p> <p>14.4 Polymeric nanosystems</p> <p>14.5 Lipid nanosystems</p> <p>14.6 Hybrid nanosystems</p> <p>14.7 Regulatory and clinical perspectives</p> <p>14.8 Conclusions</p> <p>Chapter 15: Biomaterial strategies to modulate cancer</p> <p>Abstract:</p> <p>15.1 Introduction</p> <p>15.2 Understanding cancer with biomaterials</p> <p>15.3 Molecular markers for cancer</p> <p>15.4 Biomaterials for cancer therapy</p> <p>15.5 Conclusion</p> <p>Chapter 16: 3D cancer tumor models for evaluating chemotherapeutic efficacy</p> <p>Abstract:</p> <p>16.1 Introduction</p> <p>16.2 Efforts to fight cancer</p> <p>16.3 Preclinical drug evaluation in cellular and animal models</p> <p>16.4 In vivo environment</p> <p>16.5 2D vs 3D culture systems</p> <p>16.6 3D tumor models</p> <p>16.7 Methods to culture multicellular tumor spheroids</p> <p>16.8 Conclusion</p> <p>Chapter 17: Nanotopography of biomaterials for controlling cancer cell function</p> <p>Abstract:</p> <p>17.1 Introduction</p> <p>17.2 The influence of surface topography and roughness of PLGA on cancer cells: creation of nanoscale PLGA surfaces</p> <p>17.3 The influence of nanoscale PLGA topographies on surface wettability and surface free energy</p> <p>17.4 The influence of PLGA nanotopographies on protein adsorption</p> <p>17.5 The impact of PLGA surface nanopatterns on cancer cell functions</p> <p>17.6 The impact of nanopatterns and LBL monolayers on cell functions</p> <p>17.7 Conclusions</p> <p>Index</p>